



# The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program (BMSF DCTCDP) Overview

Winter 2020/2021

# Welcome

- Welcome and Introductions
  - Catharine Grimes, Director, Bristol Myers Squibb Foundation (BMSF)
  - Joy L. Jones, Chief Program Officer, National Medical Fellowships (NMF)
- BMSF DCTCDP National Advisory Committee (NAC)
  - Robert A. Winn, MD, NAC Chair
- Program Overview
  - Catharine Grimes, MBA
  - Joy L. Jones, PhD



# Bristol Myers Squibb™ Foundation

The Bristol Myers Squibb Foundation empowers partners to build innovative solutions to advance health equity and improve access to quality healthcare for patients by focusing grant making on communities most at risk of suffering the impacts of serious diseases in the regions of the world that are hardest hit.



**NMF's vision** is to empower and support aspiring physicians and health professionals underrepresented in medicine to contribute to the health of our nation.

We envision a diverse healthcare workforce which will have the leadership, commitment and cultural competency to achieve health equity.

**NMF's mission** is to provide scholarships and support for underrepresented minority students in medicine and the health professions.



# Diversity in Clinical Trials Career Development Program (DCTCDP)

## National Advisory Committee Chair (NAC)

**Dr. Robert Winn**

Director, Massey Cancer Center  
Professor, Division of Pulmonary Disease and Critical Care Medicine  
Virginia Commonwealth University

# Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program

Catharine Grimes, MBA  
Director, Bristol Myers Squibb Foundation

Joy L. Jones, PhD  
Chief Program Officer, National Medical Fellowships

# The need for diversity in clinical trials

## Definition of Diversity in Clinical Trials

- Engage a patient population that mirrors the epidemiology of the disease studied
- Assure the ecosystem around the trials reflects diverse populations being served. Includes research sites, principal investigators, and extended care teams
- Design in inclusivity from start

## Benefits of Diversity in Clinical Trials

- Better Science. Safety and efficacy of new medicines should be assessed in the patients with the condition
- Personalized Medicine. Understanding the range of different responses to treatments based on genetic variations
- Data. Better inform treatment decisions by making new options available to patients
- Address disparity and inequity

## Current State of Clinical Trials

- Black Americans represent 13% of the US population but reflect only about 4% of participants in clinical trials
- Hispanics represent 16% of the US population but only about 3% of clinical trial participants
- In general 80% of patients taking part in clinical trials are white\*

# Diversity in Clinical Trials Career Development Program

Bristol Myers Squibb Foundation \$100 MM Commitment over 5 years

*Comprehensive and integrated approach to increase diversity in clinical trials through workforce **development AND clinical trial site development** in underserved communities where underrepresented patients receive care.*

## Do better in urban areas:

Support established clinical trials sites/centers of excellence to engage with nearby community and safety net healthcare delivery institutions to enhance their clinical trial capacity and to collaborate on research.

## Build capacity in areas with high disease burden:

Train a network of people who can help stand up a clinical trial in underserved areas that connect with community due to community outreach and engagement training, and with funding from an infrastructure fund.



# Diversity in Clinical Trials Career Development Program



## Goals

- To transform the clinical research landscape by building and strengthening partnerships between clinical investigators and the communities where their patients reside.
- To facilitate an approach to clinical and translational research that is community-informed, designed and conducted.

## Approach

- Provide training and resources to build a network of URM clinical investigators with community engagement and research skills.
- Expand the number of community-based sites with the capacity to conduct clinical and translational research.

## Outcome

Increased participation of diverse patients in clinical and translational research.

## Impact

Improved public health through an increase in the development of new drugs, vaccines and therapeutic products that are effective in all populations.


# Key Program Elements

<b>Commitment</b>	<ul style="list-style-type: none"> <li>• Train and develop 250 new clinical investigators dedicated to increasing diversity in clinical trials (~50/year)</li> <li>• Provide immersive community-based experiences in clinical trial research to 250 underrepresented minority medical students (Note: The Pipeline program will launch in the summer of 2022. Applications will open in Oct/Nov 2021).</li> </ul>
<b>Award</b>	<p>\$120K/year for 2 years; require at least 40% of Scholar's time (Note: Awards will be given to organizations, not to individuals.)</p> <p><b>Guidance for the award:</b> It is expected that the award will cover a percentage of the Scholar's salary to garner 40% of his/her time. Additionally, funds can be used toward a portion of a research assistant/coordinator salary. If funds are used for indirect costs, the amount cannot exceed \$10,000 or 10% of the recommended salary offset.</p>
<b>Mentoring</b>	Scholar will be mentored by a Principal Investigator at an established clinical trial site, and will substantively participate in the PI's active clinical trial (it is not expected that the scholar will have his/her own clinical trial). <b>Note: The clinical trial must be a drug interventional study.*</b>
<b>Training</b>	Scholars will be trained in investigator-initiated and industry-sponsored clinical trials, as well as in community outreach and engagement processes and methods.
<b>Pipeline program</b>	Scholar will serve as a mentor to an URM medical student during the 2 <sup>nd</sup> program year. 250 URM medical students (50/year) will participate in a 6- to 8-week summer immersion program learning the basics of clinical trials and working in underserved community clinics and federally qualified health centers to provide outreach, education and engagement on clinical trials. The Pipeline program will launch in the summer of 2022. Applications will open in Oct/Nov 2021.
<b>Clinical research focus areas</b>	Cancer (Hematology and Oncology), Cardiovascular Disease and Immunologic Disorders
<b>Site diversity</b>	Scholars may be practicing in urban centers / known clinical trial sites, and rural and/or trial naïve sites .
<b>Annual convening</b>	An annual event will bring key stakeholder groups together to inspire, educate, amplify and celebrate. Scholars will present their investigator-initiated clinical trial protocols in their second program year.

# Candidate Eligibility Criteria

Candidate Profile	<p>Eligible candidates will reflect the National Science Foundation (NSF) definition of underrepresented populations in the US Biomedical, Clinical, Behavioral and Social Sciences Research Enterprise:</p> <ul style="list-style-type: none"> <li>• African Americans or Blacks</li> <li>• Hispanics or Latinos</li> <li>• American Indians or Alaska Natives</li> <li>• Native Hawaiians</li> <li>• Other Pacific Islanders</li> </ul> <p>OR have a demonstrated commitment to increasing diverse patient participation in clinical trials</p>
Citizenship or Immigration Status	<p>Eligible candidates will be US Citizens or Lawful Permanent Residents (LPRs) as defined by the <a href="#">US Department of Homeland Security</a> NOTE: J-1, O-1 &amp; H-1B Visa holders are eligible; the visa must be valid during the full 2-yr period.</p>
Professional Degree	<p>Eligible candidates will hold the degree of MD, MD/PhD, DO or DO/PhD</p>
Career Phase	<p><a href="#">Early Stage Investigator (ESI)</a>: As defined by NIH, a new investigator who has completed his or her terminal research degree or medical residency—whichever date is later—within the past 10 years and has not yet competed successfully for a substantial, competing NIH research grant. (Applicants with an RO1 or RO1 equivalent are ineligible.)</p>

# BMSF DCTCDP: Timeline



# How to Apply to the BMSF DCTCDP

# Application Process with Key Target Dates

The BMSF DCTCDP application will be a 2-step process, which includes:

- 1) Submission of a [Letter of Intent \(LOI\)](#), and
- 2) Upon review, selected candidates will be invited to submit a full Application.

Application Process Opens: Letter of Intent & Invited Full Application	Jan 4, 2021
Application Closes:	July 2, 2021
Selection Process:	July 2-Aug 31, 2021
Selection Announcement:	Sep 1, 2021
First Cohort Begins:	Oct 2021

*Note: Dates are subject to change.*

# Letter of Intent - Step 1

- Degree and dates received
- List clinical specialty and sub-specialty
- Self-identify racial or ethnic minority group OR indicate Other and describe your demonstrated commitment to diversity in clinical trials
- Identify Citizenship/Immigration Status
- Position/Job title and start date
- Name and location of institution/organization
- Does your institution support your application?
- Do you have a potential mentor identified at your institution with whom you can participate on an ongoing clinical trial?
- List all current sources of funding
- List all significant publications within the last 2-3 years
- Submit current CV (within 6 months)
- Indicate your experience with the design of clinical trials studies or participation in clinical trial research
- Provide a brief description of the research you aspire to participate in during the 2-yr BMSF DCTCDP (limit 300 words)
- Provide a brief description of how you see this program advancing your career and your ability to contribute to increasing diversity in clinical trials (limit 300 words)

# National Advisory Committee (NAC)

## **CHAIR**

### **Robert Winn, MD**

Director, Massey Cancer Center  
Senior Associate Dean for Cancer Innovation  
Professor, Division of Pulmonary Disease and Critical Care Medicine  
Virginia Commonwealth University

## **MEMBERS**

### **Leon Bernal-Mizrachi, MD**

Associate Professor, Department of Hematology & Medical Oncology  
Service Chief, Hematology and Medical Oncology  
Associate Director, Hematology and Medical Oncology Fellowships Program  
Emory University School of Medicine & Grady Health Systems

### **Nancy Daly, RN, MS, MPM**

Executive Vice President & Chief Executive Officer  
Conquer Cancer and the ASCO Foundation

### **Roy S. Herbst, MD, PhD**

Ensign Professor of Medicine  
Professor of Pharmacology  
Chief of Medical Oncology  
Director, Thoracic Oncology Research Program  
Associate Director for Translational Research  
Yale Comprehensive Cancer Center  
Yale School of Medicine

### **Gail Kerr, MD, FRCP**

Professor of Medicine & Chief of Rheumatology at  
Howard University Hospital  
Howard University

### **José López, MD**

Chief Scientific Officer & Full Member  
Blood Works Northwest Research Institute  
Professor of Medicine, Division of Hematology  
University of Washington School of Medicine

### **Ruben Mesa, MD, FACP**

Presidential Chair, Mays Family Foundation  
Distinguished University  
Director, Mays Cancer Center  
Professor of Medicine  
UT Health San Antonio MD Anderson

### **Lucio Miele, MD, PhD**

Professor and Department Head, LSU School of Medicine, Department of Genetics  
Director for Inter-Institutional Programs, LSU Stanley Scott Cancer Center & Louisiana Cancer Research Consortium  
Cancer Crusaders Endowed Professor in Cancer Research  
Louisiana State University Health Sciences Center

### **Edith Mitchell, MD, MACP, FCPP**

Clinical Professor of Medicine and Medical Oncology  
Director, Center to Eliminate Cancer Disparities  
Associate Director, Diversity Affairs  
Sidney Kimmel Cancer Center at Jefferson Health

### **Kathryn Owen**

Vice President  
Head of Global Development Operations  
Bristol Myers Squibb

### **Eliseo J. Pérez-Stable, MD**

Director, National Institute on Minority Health and Health Disparities  
National Institutes of Health

### **Lori Pierce, MD**

Professor, Department of Radiation Oncology  
Vice Provost for Academic and Faculty Affairs  
Michigan Medicine, University of Michigan

### **Amelie G. Ramirez, DrPH, MPH**

Director & Professor, Institute for Health Promotion Research, Graduate School of Biomedical Sciences  
UT Health San Antonio

### **Brian Rivers, PhD, MPH**

Director, Cancer Health Equity Institute, National Center for Primary Care  
Morehouse School of Medicine

### **Hannah Valantine, MD**

Professor, Cardiovascular Medicine  
Stanford University Medical Center  
Prior: Chief Officer for Scientific Workforce Diversity, National Institutes of Health

### **Annabelle Volgman, MD, FACC, FAHA**

McMullan-Eybel Chair of Excellence in Clinical Cardiology  
Professor of Medicine, Rush College of Medicine  
Medical Director, Rush Heart Center for Women  
Rush University

### **Karen Winkfield, MD, PhD**

Executive Director  
Meharry-Vanderbilt Alliance  
Vanderbilt University Medical Center

### **Winston Wong, MD, MS, FAAFP**

Scholar-in-Residence, UCLA Kaiser Permanente Center for Health Equity  
UCLA Fielding School of Public Health



# QUESTIONS

# Thank you for your interest in the BMS Foundation DCTCDP!

Letter of intent:

<https://nmf.smapply.io/prog/bmsf-dctcdp/>

Direct inquiries to: [DCTCDPinfo@nmfonline.org](mailto:DCTCDPinfo@nmfonline.org)

Program website: [www.diversityinclinicaltrials.org](http://www.diversityinclinicaltrials.org)